Industry News
Biotechnology Industry News
Cardiovascular (CV) disease is a…
Cardiovascular (CV) disease is a leading cause of death among patients with prostate cancer.
Windtree Therapeutics has not been…
Windtree Therapeutics has not been shy about its desire to become a revenue-generating company, even when achieving that goal means stepping outside the world of drug development. Now, the company is further divesting itself from
William Blair has hand-picked its…
William Blair has hand-picked its top five stock recommendations for 2026, selections that include three clinical-stage biotechs in the bunch.
Hope Biosciences has linked its…
Hope Biosciences has linked its stem cell therapy candidate to improved motor function in Parkinson’s disease patients in a phase 2 trial.
Despite a year of trade tensions,…
Despite a year of trade tensions, national security strictures and stark warnings about the United States’ waning biotech innovation edge, the fact remains that China is and will likely continue to be a prominent source
Six people, including a former…
Six people, including a former employee of investment bank Citigroup’s San Francisco office, have been charged in an alleged $41 million insider trading and stock manipulation scheme that involves two biotech companies.
Amid news of the splashy $4.8…
Amid news of the splashy $4.8 billion Amicus buy, BioMarin has slipped in the discontinuation of a genetic lung disease candidate it had once hoped would become a best-in-class treatment.
Two years after Gilead secured the…
Two years after Gilead secured the first option on Assembly Biosciences’ entire pipeline, the pharma has decided to pick the first fruits from the pact.
Boehringer Ingelheim has opened…
Boehringer Ingelheim has opened another front in its attack on chronic kidney disease, offering Rectify Pharmaceuticals up to $448 million to partner on a preclinical program.
Big Pharma-backed Aktis Oncology…
Big Pharma-backed Aktis Oncology has announced plans to go public in the latest encouraging sign for those betting on a resurgence in biotech IPOs next year.
Having kicked off the year with a…
Having kicked off the year with a $200 million series A, Windward Bio is ending 2025 splashing out on another clinical-stage drug.
Ipsen may be a recent entrant into…
Ipsen may be a recent entrant into the antibody-drug conjugate space, but the French biopharma is continuing to make up for lost time.
AstraZeneca has fronted $100…
AstraZeneca has fronted $100 million to head deeper into the KRAS space, securing the rights to a clinical-stage, multitarget asset from China’s Jacobio Pharma.
Ipsen’s oral small molecule…
Ipsen’s oral small molecule failed to reduce the progression of a genetic disease that gradually turns tendons and ligaments into bone, prompting the pharma to stop the study early.
Venture capital firm Aditum Bio is…
Venture capital firm Aditum Bio is going all-out for a new collaboration with Fosun Pharma, launching a subsidiary with the sole purpose of developing novel therapies in tandem with the Shanghai-based drugmaker.
Merck & Co. is turning down…
Merck & Co. is turning down its option to license Evaxion’s gonorrhea vaccine candidate, closing the door on the Danish biotech’s chance to collect up to $592 million in biobucks.
Altimmune has shared an update on…
Altimmune has shared an update on the metabolic dysfunction-associated steatohepatitis (MASH) study that sank its stock in June. The 48-week readout linked the top dose of the GLP-1/glucagon dual receptor agonist to continued weight loss
Boehringer Ingelheim has turned…
Boehringer Ingelheim has turned down its chance to license Nxera Pharma’s phase 2-ready schizophrenia drug candidate, depriving the Japanese drugmaker of a 60 million euro ($70 million) option payment.
Longtime Pfizer R&D…
Longtime Pfizer R&D chief Kathy Fernando, Ph.D., has left the Big Pharma behind to take on the role of chief business officer at San Diego biotech Replicate Bioscience. There, she’ll work to advance Replicate’s early-stage pipeline
After a long and strange year,…
After a long and strange year, Belgian biotech Galapagos is closing out 2025 with some mixed results for its last remaining immunology asset. The company’s tyrosine kinase 2 inhibitor GLPG3667 met the primary endpoint in